SAN DIEGO, Oct. 11 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it was issued US patent number 6,953,787,
entitled "5-HT2C Receptor Modulators," by the United States Patent and
Trademark Office. The patent relates to novel compounds that modulate the
5-HT2C serotonin receptor, which helps reg...
SAN DIEGO, Oct. 10 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that the company will release its financial
results for the third quarter of 2005 after the Nasdaq National Market closes
on Monday, October 17, 2005. That same afternoon Jack Lief, Arena's President
and Chief Executive Officer, and R...
SAN DIEGO, Sept 22, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it will present at the UBS Global Life
Sciences Conference on Wednesday, September 28, 2005, at 1:30 p.m. Eastern
Time (10:30 a.m. Pacific Time) at The Grand Hyatt in New York City. Jack
Lief, Arena's Pr...
SAN DIEGO, Sept. 1 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company will be presenting at five
investor conferences during September 2005 during which it will present a
corporate overview of the company and its clinical development and discovery
programs. The conference information is...
SAN DIEGO, Aug 25, 2005 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that an assessment of follow-up echocardiograms
taken approximately 90 days after patients received their first doses of
APD356 in its Phase 2a clinical trial indicates no apparent drug effect on
heart valves or pulmonary a...
SAN DIEGO, Aug. 11 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it was granted patent number 1133559,
entitled "HUMAN ORPHAN G PROTEIN-COUPLED RECEPTOR RUP3," by the European
Patent Office. The patent relates to certain drug screening methods utilizing
the 19AJ receptor, an orphan G protein-c...
SAN DIEGO, July 26 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that Merck & Co., Inc. initiated a Phase 1
clinical trial of an orally administered drug candidate being developed in
partnership with Merck for the treatment of atherosclerosis and related
disorders. The initiation of the Phase 1...
SAN DIEGO, July 19, 2005 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today reported financial results for the second quarter and six
months ended June 30, 2005.
Total revenues in the second quarter of 2005 were $5.5 million, compared
to $1.4 million in the second quarter of 2004. Total revenues in...
SAN DIEGO, July 11 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that the company will release its financial
results for the second quarter of 2005 before the NASDAQ National Market closes
on Tuesday, July 19, 2005. Arena also announced today that Jack Lief, Arena's
President and Chief Executive Of...
SAN DIEGO, June 30, 2005 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today top-line results from its Phase 1 clinical
trials of APD125, Arena's orally administered, internally discovered drug
candidate for the treatment of insomnia. APD125 was well tolerated at all
doses investigated. The data ...
SAN DIEGO, June 23 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it started dosing patients in a Phase 2b
clinical trial of APD356, Arena's orally administered, internally discovered
drug candidate for the treatment of obesity. The trial will evaluate safety
and weight loss in approximately 40...
SAN DIEGO, June 17 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it will present an abstract entitled "The
Selective Serotonin 5-HT2A Inverse Agonist APD125 Promotes Sleep Onset and
Consolidation" at the Associated Professional Sleep Societies (APSS) meeting
in Denver on June 22, 2005.
...
SAN DIEGO, June 17, 2005 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that Jack Lief, Arena's President and CEO, will
participate in a panel entitled "Sustaining a Burn: Strategies to Fund
Pipeline Development" at the BIO 2005 Annual International Convention in
Philadelphia, PA, on Wednesday...
SAN DIEGO, June 7, 2005 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it was issued U.S. patent number
6,902,902, entitled "Human G Protein-Coupled Receptors and Modulators Thereof
for the Treatment of Metabolic-Related Disorders," by the U.S. Patent Office.
The patent relates to certain...
SAN DIEGO, May 26 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that its New York City Analyst and Investor Day
will be webcast live on Thursday, June 2, 2005, at approximately 12:00 p.m.
Eastern Time (9:00 a.m. Pacific Time). Jack Lief, President and Chief
Executive Officer, Dominic P. Behan, Ph.D...
SAN DIEGO, May 19 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that it will present a corporate update at the
Fourth Annual Needham Biotechnology Conference on Wednesday, May 25, 2005, at
9:00 a.m. Eastern Time (6:00 a.m. Pacific Time). Dominic P. Behan, Ph.D.,
Senior Vice President and Chief Scie...
SAN DIEGO, May 11 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today positive top-line results from its Phase 2
clinical trial of APD356, Arena's orally administered, internally discovered
drug candidate for the treatment of obesity. Over the 28 day treatment
period, there was a highly statistically sig...
SAN DIEGO, May 4 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it was granted patent number 03 718 323,
entitled "5-HT2C Receptor Modulators," by the European Patent Office. The
patent relates to novel compounds that modulate the 5-HT2C serotonin receptor,
which is thought to be involved in th...
SAN DIEGO, April 26, 2005 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today reported financial results for the first quarter ended
March 31, 2005.
Total revenues in the first quarter of 2005 were $4.4 million, compared to
$5.8 million in the first quarter of 2004. Arena reported a net loss
alloc...
SAN DIEGO, April 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that the company will release its financial
results for the first quarter of 2005, after the NASDAQ National Market closes
on Tuesday, April 26, 2005. Arena also announced today that Jack Lief,
President and Chief Executive Officer, w...
